Technology area: Chemistry & Materials
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Innopoly Biotech (Hangzhou) Inc. is managing 2 pending office actions in the Chemistry & Materials technology area. Both of these actions are assigned to 1 distinct examiner, KAUCHER, MARK S, and are located within 1 distinct art unit. This represents a concentration of the workload, as a single examiner is responsible for the 2 pending office actions. The centralization in 1 distinct art unit and with 1 distinct examiner means that prosecution strategy can be consistently applied across all pending matters.
KAUCHER, MARK S holds 2 pending office actions, which is the total number of actions for the company. This busiest examiner is responsible for all active matters in the current prosecution pipeline. Practitioners should focus on the specific preferences of this 1 distinct examiner, as they review the company's 2 pending office actions. This administrative structure simplifies the management of the portfolio's active applications by limiting the number of distinct examiners and art units involved. The presence of 2 pending office actions under 1 distinct examiner allows for a highly consolidated response strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUCHER, MARK S | 2 | 72.5% | +14.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18479537 | POLYMER CAPABLE OF FORMING ELASTIC MATERIAL BY THERMAL CROSSLINKING, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KAUCHER, MARK S | — |
| 18479545 | THERMALLY CROSS-LINKABLE POLYMER FOR FORMING ELASTIC MATERIAL USED AS FOLDABLE INTRAOCULAR LENS, PREPARATION METHOD THEREFOR AND USE THEREOF | KAUCHER, MARK S | — |
| Art Unit | Apps |
|---|---|
| 1764 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18479537 | POLYMER CAPABLE OF FORMING ELASTIC MATERIAL BY THERMAL CROSSLINKING, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KAUCHER, MARK S | 1764 | §102§103§112DP | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18479545 | THERMALLY CROSS-LINKABLE POLYMER FOR FORMING ELASTIC MATERIAL USED AS FOLDABLE INTRAOCULAR LENS, PREPARATION METHOD THEREFOR AND USE THEREOF | KAUCHER, MARK S | 1764 | §102§103§112DP | Non-Final OA | — | Pending | Oct 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnopoly Biotech (Hangzhou) Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mark S Kaucher has the most, with 2 of Innopoly Biotech (Hangzhou) Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
